Biometrics giant Zimmer acquires Monogram Technologies in a $177 million transaction.

Zimmer Biomet Acquires Monogram Technologies for $177 Million

Zimmer Biomet, a global leader in medical technology, has announced its acquisition of Monogram Technologies, an orthopedic robotics company, for approximately $177 million in equity value. The deal is set to broaden Zimmer Biomet's orthopedic robotics and enabling solutions, addressing diverse surgical needs.

Ivan Tornos, Chairman, President, and CEO of Zimmer Biomet, stated that Monogram's technology is a major leap forward, demonstrating Zimmer Biomet's commitment to becoming the boldest and broadest innovator in surgical robotics and navigation.

Monogram's CT-based, semi-autonomous, AI-navigated total knee arthroplasty (TKA) robotic technology, which received FDA 510(k) clearance in March 2025, is expected to be commercialized with Zimmer Biomet implants in early 2027.

Ben Sexson, CEO of Monogram Technologies, led the company during its agreement to be acquired by Zimmer Biomet. Upon closing, Zimmer Biomet's customer-centric portfolio will consist of the most comprehensive and flexible technology ecosystem to support the varying preferences of a vast array of surgeons, now and into the future.

The acquisition will integrate Monogram's robotic technologies into Zimmer Biomet's ROSA Robotics platform, which remains a cornerstone for Zimmer Biomet, with new products and software applications expected by 2027. Monogram is developing a fully autonomous version of its TKA robotic technology, aiming to make Zimmer Biomet the first company in orthopedics to offer a fully autonomous surgical robot.

With Monogram's proprietary technology, Zimmer Biomet has the potential to become the first company to deliver fully autonomous capabilities and redefine both the standard of care and the future of orthopedic surgery.

Monogram is thrilled by the opportunity to add its technology to Zimmer Biomet's leading portfolio of surgical robotics, navigation solutions, and trusted implants, and to benefit from their deep industry expertise and global scale.

Stockholders of Monogram will receive a non-tradeable contingent value right (CVR) potentially worth up to $12.37 per share based on future milestones. The transaction is subject to regulatory and stockholder approvals and is expected to close later this year.

Ben Sexson, CEO of Monogram, expressed that since its inception, Monogram has been singularly focused on advancing orthopedic robotics with technology designed to safely, efficiently, and accurately support surgeons with total knee arthroplasty.

Morgan Stanley, Hogan Lovells, Wells Fargo Securities, and Duane Morris are serving as advisors for the respective parties in the acquisition. Zimmer Biomet anticipates the acquisition will be neutral to adjusted earnings per share in 2025-2027 and accretive from 2028 onward.

Biometrics giant Zimmer acquires Monogram Technologies in a $177 million transaction.